Cell Signalings and the Communications in Head and Neck Cancer by Yuh Baba Masato Fujii Yutaka Tokumaru & Yasumasa Kato
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Cell Signalings and the  
Communications in Head and Neck Cancer 
Yuh Baba1,2,3, Masato Fujii2, Yutaka Tokumaru2 and Yasumasa Kato3 
1Department of Otolaryngology, Ohtawara Red Cross Hospital, Ohtawara 
2National Institute of Sensory Organs, National Tokyo Medical Center, Tokyo 
3Department of Oral Function and Molecular Biology, Ohu University,  
Misumido Tomita-machi Koriyama, 
Japan 
1. Introduction 
HNSCC (head and neck squamous cell carcinoma) is the sixth most common neoplasm 
worldwide (Cripps et al., 2010). Approximately 600,000 new cases are reported each year 
(Cripps et al., 2010), and in the past 30 years recurrent and/ or metastatic HNSCC has had a 
poor prognosis (Forastiere et al., 2001; Khuri et al., 2000). More than 50% of newly 
diagnosed patients do not achieve complete remission, and in approximately 10% of 
HNSCC cases relapse with metastasis to distant organs has been reported (van Houten et 
al., 2000). Therefore, research focused on gaining a better understanding of this disease and 
the development of novel treatment strategies is required. 
Epidermal growth factor receptor (EGFR), a ubiquitously expressed transmembrane 
glycoprotein belonging to the ErbB/HER family of receptor tyrosine kinases (TK), is 
composed of an extracellular ligand-binding domain, a hydrophobic transmembrane 
segment and an intracellular TK domain. When ligands bind to EGFR the receptor 
undergoes a conformational change that promotes homo- or hetero-dimerization with other 
members of the ErbB/HER family of receptors; subsequent autophosphorylation and 
activation of the TK domain ensues (Ciardiello  Tortora, 2003). Activation of EGFR leads to 
activation of intracellular signaling pathways that regulate cell proliferation, invasion, 
angiogenesis and metastasis. 
EGFR is expressed at high levels in the majority of epithelial malignancies including 
HNSCC. Elevated expression of EGFR in HNSCC correlates with poor prognosis, and it has 
long been a target of anticancer treatments owing to its critical role in cell survival and 
proliferation. Numerous tyrosine kinase inhibitors with the Food and Drug Administration 
(FDA) approval have been developed to target EGFR including gefitinib, erlotinib and 
lapatinib (Carter et al., 2009). These molecules are reversible competitors, competing with 
ATP for the tyrosine kinase binding domain of EGFR. By inhibiting receptor activation, 
downstream signaling pathways are inhibited, leading to a decrease in cell proliferation and 
survival. EGFR signaling activates a number of downstream effectors including the 
phosphatidylinositol-3-kinase (PI3Kinase)/Akt pathway. 
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2. Rare EGFR mutations in HNSCC 
Somatic mutations in the TK domain of the EGFR gene (in-frame deletion in exon 19, L858, 
G719X and L861Q) are associated with increased sensitivity to EGFR tyrosine kinase 
inhibitors (TKIs) and are present in 10~30% of non-small cell lung carcinoma (NSCLC) cases 
depending on ethnic origin. These mutant EGFRs selectively activate signal transduction 
and activator of transcription (STAT) signaling pathways and Akt, which promote cell 
survival. However, they have no effect on extracellular signal-regulated kinase signaling, 
which induces proliferation. Furthermore, mutant EGFRs selectively transduce survival 
signals, and inhibition of those signals by TKIs could contribute to the efficacy of a drug 
used to treat NSCLC (Sordella et al., 2004). However, molecular analysis of HNSCC tumor 
samples has not revealed the same spectrum of mutations (Loeffler-Ragg et al., 2006; Ozawa 
et al., 2009; Taguchi et al., 2008).  
A resistance mutation has emerged in EGFR and is known as T790M. It is a missense 
mutation in the kinase domain that could help to explain resistance to TKIs in NSCLCs 
exhibiting L858R (Wong, 2008). However, we did not detect this mutation in 86 HNSCC 
tumor samples (Baba et al., 2011). 
3. Inhibition of PI synthesis in HNSCC 
3.1 Anti-proliferation 
An imbalance between G1 cyclin and CDK (cyclin-dependent kinase) inhibitors (CKIs) 
contributes to tumorigenesis and tumor progression. Cyclin D1/PRAD1 acts as a positive 
regulator of the cell cycle via phosphorylaton of pRB (Rb protein), and the formation of a 
cyclin D1-CDK4 complex. When pRB is hyperphosphorylated by CDKs, pRB release E2F, 
and E2F is necessary for the activation of a gene expression network that regulates entry and 
progression through S phase. 
CKIs are classified into two groups: members of the Ink4 family (p15, p16, p18, and p19) for 
cyclin D/CDK4 or cyclin D/CDK6, and the cip/kip family (p21, p27, and p57) for cyclin 
D/CDK4 and cyclin E/CDK2 (Baba et al., 2000a). Over-expression of cyclin D1 in HNSCC is 
an important prognostic marker, predicting sensitivity to chemotherapy and radiotherapy 
(Fujii et al., 2001; Ishiguro et al., 2003; Nishimura et al., 1998). Furthermore, imbalance 
between cyclin D1 and its inhibitors (p16 and p27) could be critical in the development of 
HNSCC (Baba et al., 1999, 2001a). Strategies to block cyclin D1 function have been studied 
extensively; for example, Nakashima et al. (Nakashima  Clayman, 2000) reported that 
introduction of an antisense cyclin D1 expression vector into cells reduced their growth rate 
in vitro and decreased tumorigenicity in athymic nude mice. We have previously reported 
that inhibition of PI synthesis caused G1 arrest of HNSCC accompanied by decreased levels 
of cyclin D1, cyclin E and phosphorylated pRB (Baba et al., 2001b). 
3.2 Inhibition of matrix metalloproteinase (MMP) production/ activity 
Tumor metastasis is a complex multistep process including growth at the primary site, entry 
into the circulation (intravasation), adhesion to the basement membranes (BM) of target 
organs, extravasation and growth at secondary sites. Among these steps, the intravasation 
and extravasation processes involve degradation of the BM by proteinases, such as some 
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MMPs. MMP-9/gelatinase B and MMP-2/gelatinase A have specificity for type IV collagen, 
which acts as the backbone of BM, and therefore probably play a major role in degrading the 
BM. In HNSCC, MMP-2 and MMP-9 are associated with metastatic potential. Indeed, 
inhibition of MMP-2 and MMP-9 production lead to repress invasive activity of HNSCC 
cells (Baba et al., 2000b). Therefore, MMPs are attractive therapy targets and many drugs 
have been developed to prevent their extracellular matrix-degrading activities during 
metastasis and angiogenesis. 
3.3 Anti-angiogenesis 
Angiogenesis, the formation of new blood vessels from pre-existing capillaries or 
incorporating bone marrow-derived endothelial precursor cells into growing vessels, is 
associated with the malignant phenotype of cancer. In addition, it also plays a role in 
diverse diseases such as diabetic retinopathy, age-related macular degeneration, rheumatoid 
arthritis, psoriasis, atherosclerosis and restenosis (Cherrington et al., 2000). Clinical 
association of tumor vascularity with tumor aggressiveness has been demonstrated in a 
wide variety of tumor types including HNSCC. Therefore, determining microvessel density 
in tumor tissues can be useful in the estimation of a patient’s prognosis. Inhibition of 
angiogenesis can repress the growth rate of tumor cells and lead to cell death resulting from 
reduced nutrition and oxygen supply to the tumor. VEGF (vascular endothelial growth 
factor), which plays a major role in many angiogenic processes, binds to its receptor Flk-
1/KDR in order to stimulate endothelial cell (EC) proliferation through the phospholipase 
CǄ-protein kinase C-ERK (extracellular signal-regulated kinase) pathway, but not via Ras 
(Takahashi et al., 1999). In addition, VEGF stimulates EC migration through p38 MAPK 
(mitogen-activated kinase) independently of ERK (Rousseau et al., 1997). Therefore, these 
two major MAPK pathways are eligible targets for therapeutic reduction of angiogenesis  
in HNSCC. 
Most clinical trials concerning anti-angiogenic agents have been conducted in patients with 
advanced disease that had become resistant to conventional therapies. Phase III trials of 
these agents have compared the efficacy of standard chemotherapy alone and in 
combination with an experimental angiogenesis inhibitor (Gotink  Verheul, 2010). The 
results of some studies were negative or controversial, but several recent clinical trials in 
which VEGF signaling was blocked demonstrated a significant clinical benefit (Ho  Kuo, 
2007). SU11248, a tyrosine kinase inhibitor of the Flk-1/KDR receptor (VEGF receptor) and 
bevacizumab, a monoclonal antibody to VEGF, have been approved by FDA (Ho  Kuo, 
2007). Furthermore, we have demonstrated that the inhibition of PI abrogated stimulation 
by VEGF on the growth and migration of human umbilical vein ECs through the ERK-cyclin 
D1 and p38 pathways, respectively (Baba et al., 2004). Because increased PI synthase 
expression is an early event in HNSCC (Kaur et al., 2010), inhibition of PI synthesis could be 
a potent therapeutic strategy for HNSCC (Baba et al., 2010).  
4. Resistance to EGFR TKIs 
In a phase II trial gefitinib was administered to patients with recurrent or metastatic HNSCC 
and the overall response rate was 11% (Cohen et al., 2003). Furthermore, in a similar study 
carried out on patients with recurrent and /or metastatic HNSCC, the response rate to 
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erlotinib was 4% (Soulieres et al., 2004). This is suggesting that multiple intracellular 
signaling pathways are involving to associate tumor survival, growth, and the other 
malignant phenotype. 
4.1 Ras mutations 
Previous reports have indicated that activating K-ras mutations could induce activation of 
the Ras/mitogen activated protein kinase (MAPK) pathway independent of EGFR, which in 
turn induces resistance to TKIs (Eberhard et al., 2005). The data suggest that K-ras mutation 
causes insensitivity to TKIs. In HNSCC, H-ras mutations are more common than K-ras 
mutations and may play an important role in resistance to EGFR-targeted therapies 
(Anderson et al., 1994). 
4.2 Epithelial-Mesenchymal Transition (EMT) 
EMT, a change in the morphology and motility of cells that is indicated by increased vimentin 
expression, decreased expression of E-cadherin and increased expression of claudins 4 and 7, 
has been associated with gefitinib resistance in HNSCC (Frederick et al., 2007). 
4.3 Upregulation of cyclin D1 
Upregulation of cyclin D1 in HNSCC cell lines is specifically associated with resistance to 
gefitinib; retinoblastoma protein (pRb) is hyperphosphorylated by cyclin D1-cyclin 
dependent kinase 4 (CDK4) (Kalish et al., 2004). 
4.4 Cortactin 
Recently, increased expression of cortactin, a protein that increases the formation of actin 
networks critical to cell motility and receptor-mediated endocytosis, has been associated 
with gefitinib resistance and increased metastasis in HNSCC (Timpson et al., 2007). 
Akt has been implicated in EMT by integrin-linked kinase (ILK). The PI3Kinase/Akt 
pathway not only regulates the transcriptional activity of cyclin D1, but also increases its 
accumulation by inactivating glycogen synthase kinase-3 (GSK3), which targets cyclin D1 
for proteasomal degradation. The effect of cortactin on cancer cell proliferation is associated 
with increased activation of Akt (Timpson et al., 2007). Therefore, factors related to 
resistance to EGFR TKIs are associated with the PI3kinase/Akt pathway.  
5. PI3kinase/Akt pathway 
5.1 Activation of the PI3kinase/Akt pathway 
Signaling through the PI3kinase/Akt pathway can be initiated by several mechanisms, all of 
which increase activation of the pathway in cancer cells. Once activated, the PI3kinase/Akt 
pathway can be propagated to various substrates including mTOR, a master regulator of 
protein translation. The pathway is initially activated at the cell membrane, where the signal 
for activation is propagated through class IA PI3kinase. Activation of PI3kinase can occur 
through tyrosine kinase receptor for EGF and insulin-like growth factor-1 (IGF-1). Integrins 
and G-protein-coupled receptors (GPCRS) are also known to activate it. PI3kinase catalyzes 
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phosphorylation of the D3 position on phosphoinositides to generate the biologically active 
moieties phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3) and phosphatidylinositol-3,4- 
bisphosphate (PI(3,4)P2). PI(3,4,5)P3 binds to the pleckstrin homology (PH) domains of 
PDK-1 (3’-phosphoinositide-dependent kinase 1) and Akt, resulting in the proteins being 
translocated to the cell membrane where they are subsequently activated. The tumor 
suppressor PTEN (phosphatase and tensin homolog deleted on chromosome ten) 
antagonizes PI3kinase by dephosphorylating PI (3,4,5)P3 and (PI(3,4)P2), thereby preventing 
activation of Akt and PDK-1. Akt exists as three structurally similar isoforms, Akt1, Akt2 
and Akt3, which are expressed in most tissues. Activation of Akt1 occurs through two 
crucial phosphorylation events. The first, carried out by PDK-1, occurs at T308 in the 
catalytic domain. Full activation requires a subsequent phosphorylation at S473 in the 
hydrophobic motif, which can be mediated by several kinases including PDK-1, ILK, Akt 
itself, DNA-dependent protein kinase and mTOR; phosphorylation of homologous residues 
in Akt2 and Akt3 occurs by the same mechanism. Phosphorylation of Akt at S473 is 
controlled by a recently described phosphatase, PHLPP (PH domain leucine-rich repeat 
protein phosphatase), that has two isoforms that preferentially decrease activation of 
specific Akt isoforms (Brognard et al., 2007). Amplification of Akt1 has been described in 
human gastric adenocarcinoma, and amplification of Akt2 has been described in ovarian, 
breast and pancreatic carcinoma (Bellacosa et al., 1995; Cheng et al., 1996). Although Akt 
mutations are rare, Carpten et al. (Carpten et al., 2007) recently described somatic mutations 
occurring in the PH domain of Akt1 in a small percentage of human breast, ovarian and 
colorectal cancers.  
5.2 Downstream substrates of activated Akt 
Akt recognizes and phosphorylates the consensus sequence RXRXX (S/T) when it is 
surrounded by hydrophobic residues. This sequence is present in many proteins resulting in 
numerous Akt substrates being identified and validated. These substrates control key 
cellular processes such as apoptosis, cell cycle progression, transcription and translation. For 
example, Akt phosphorylates the FoxO subfamily of forkhead family transcription factors, 
inhibiting transcription of several pro-apoptotic genes including Fas-L, IGF Binding 
Protein1 (IGFBP1) and Bim. Additionally, Akt can directly regulate apoptosis by 
phosphorylating and inactivating pro-apoptotic proteins such as BAD, which controls the 
release of cytochrome c from mitochondria, and apoptosis signal-regulating kinase-1 
(ASK1), a mitogen-activated protein kinase kinase involved in stress- and cytokine-induced 
cell death. In contrast, Akt can phosphorylate IkappaBalpha kinase (IKK), which indirectly 
increases the activity of nuclear factor kappa B (NFκB) and stimulates the transcription of 
pro-survival genes. Cell cycle progression can also be affected by Akt; inhibitory 
phosphorylation of the cyclin-dependent kinase inhibitors p21 and p27, and inhibition of 
GSK3ǃ by Akt, stimulates cell cycle progression by stabilizing cyclin D1 expression. A novel 
pro-survival Akt substrate, PRAS40 (proline-rich Akt substrate of 40kDa), has been 
described recently (Vander Haar et al., 2007). Phosphorylation of PRAS40 by Akt attenuates 
its ability to inhibit mTORC1 kinase activity. It has been suggested that PRAS40 could be a 
specific substrate of Akt3 (Madhunapantula et al., 2007). Therefore, Akt inhibition could 
have pleiotropic effects on cancer cells that contribute to an anti-tumor response. The most-
studied downstream substrate of Akt is the serine/threonine kinase mTOR (mammalian 
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target of rapamycin). Akt can directly phosphorylate and activate mTOR, and indirectly 
activate it by phosphorylating and inactivating TSC2 (tuberous sclerosis complex 2, also 
called tuberin), which normally inhibits mTOR through the GTP binding protein Rheb 
(Ras homolog enriched in brain) (Inoki et al., 2003). When TSC2 is inactivated by 
phosphorylation, the GTPase Rheb is maintained in its GTP-bound state, allowing 
increased activation of mTOR (Inoki et al., 2005). mTOR exists in two complexes: the 
TORC1 complex, in which mTOR is bound to Raptor; and the TORC2 complex, in which 
mTOR is bound to Rictor. In the TORC1 complex, mTOR signals to its downstream 
effectors S6 kinase/ribosomal protein and 4EBP-1/eIF-4E, to control protein translation 
(Inoki et al., 2005). mTOR is generally considered to be a downstream substrate of Akt, 
but it can phosphorylate Akt when bound to Rictor in TORC2 complexes (Sarbassov et al., 
2005), and this could provide positive feedback in the pathway. In addition, the 
downstream mTOR effector S6 kinase-1 (S6K1) can regulate the pathway by catalyzing an 
inhibitory phosphorylation on insulin receptor substrate (IRS) proteins. This prevents  
IRS proteins from activating PI3kinase, thereby inhibiting activation of Akt (Harrington et 
al., 2004). 
5.3 Rationale for targeting the PI3kinase/Akt pathway 
In addition to preclinical studies, clinical observations support the targeting of the 
PI3kinae/Akt/mTOR pathway in human cancer (Vogt et al., 2009). Immunohistochemical 
studies using antibodies that recognize Akt phosphorylated at S473 have demonstrated 
that activated Akt is detectable in cancers including head and neck cancer (Gupta et al., 
2002). Tsurutani et al. (Tsurutani et al., 2006) recently extended these studies using 
antibodies against S473 and T308, two sites of Akt phosphorylation. This study 
demonstrated that Akt activation is selective for NSCLC versus normal tissue, and that 
phosphorylation of Akt at both sites is a better predictor of poor prognosis in NSCLC than 
phosphorylation of S473 alone. In addition, amplification of Akt isoforms has been 
observed in some cancers, albeit at a lower frequency. Another frequent genetic event 
occurring in human cancer is loss of function of the tumor suppressor PTEN. PTEN 
normally suppresses activation of the PI3kinase/Akt/mTOR pathway by functioning as a 
lipid phosphatase. Loss of PTEN function in cancer can occur through mutation, deletion 
or epigenetic silencing. In tumor types where PTEN mutations are rare such as lung 
cancer, epigenetic silencing can occur (Forgacs et al., 1998). Several studies have 
demonstrated the prognostic significance of PTEN loss in multiple human cancers where 
mutation, deletion or epigenetic silencing of PTEN correlates with poor prognosis and 
reduced survival (Bertram et al., 2006). Collectively, these studies have established that 
the loss of PTEN is a common mechanism for activation of the PI3kinase/Akt/mTOR 
pathway and led to poor prognostic factor in human cancer. Activation of PI3Kinase has 
been described in human cancers. It can result from amplification, over-expression, or 
mutations in the p110 catalytic or p85 regulatory subunits. Amplification of the 3q26 
chromosomal region, which contains the gene PI3KCA that encodes the p110ǂ catalytic 
subunit of PI3K, occurs in 40% of ovarian and 50% of cervical carcinomas (Ma et al., 2000; 
Shayesteh et al., 1999). Somatic mutations of this gene have been detected in several 
cancer types and result in increased kinase activity of mutant PI3K relative to wild-type 
PI3K (Samuels  Ericson, 2006). Mutations in the regulatory p85 subunit have also been 
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detected. Any of the aforementioned alterations in individual components would result in 
activation of the PI3 kinase/Akt pathway, and studies suggest that pathway activation is 
one of the most frequent molecular alterations that occur in cancer (Samuels   
Ericson, 2006). 
6. Cross talk between the IGF1 receptor (IGF1R) and EGF receptor (EGFR) 
pathways through PI3 kinase/Akt 
The phenomenon of growth factors switching from one pathway to another has an 
adaptive component, which could be induced by blocking the dominant growth factor 
receptor pathway. Blockade of EGFR signaling has been demonstrated to result in the 
enhancement of the growth promoting effects of the peptide growth factor ligands basic 
fibroblast growth factor and IGF-1 in DU145 and PC-3 human prostate cancer cells, 
respectively (Jones et al., 1997). More recently, the substantial growth inhibitory effects of 
the EGFR-selective tyrosine kinase inhibitor gefitinib on EGFR-positive MCF-7-derived 
tamoxifen-resistant breast cancer cells, has been demonstrated. Furthermore, this effect 
can be subverted by additionally exposing cells to non-EGF ligands such as heregulin-ぁ 
and IGF-II (Knowlden et al., 2005). The reversal of the anti-tumor effects of gefitinib by 
IGF-II, acting through the IGF-1R, is accompanied by a reactivation of the previously 
reduced activity of Akt and extracellular-regulated kinase (ERK); ERK signaling 
contributes to the re-establishment of tumor cell growth. Therefore, in the presence of a 
dominant growth pathway, cancer cells are capable of responding to other growth factors 
that are present, thereby compromising the anti-tumor activity of agents designed 
specifically to inhibit EGFR. Importantly, a previous study demonstrated that following 
blockade of EGFR signaling, switching to the IGF-1R pathway is a common mechanism 
used to promote resistance to anti-EGFR treatment (Choi et al., 2010). For example, 
gefitinib initially inhibited the growth of the EGFR-positive cell lines DU145 (prostate 
cancer cells) and MCF-7-derived tamoxifen- and fulvestrant resistant breast cancer cell 
lines, but chronic challenge with the inhibitor resulted in the development of gefitinib-
resistant variant sub-lines, all of which presented with up-regulation of multiple IGF-1R 
signaling components when compared with the parental cell lines (Jones et al., 2004). This 
resulted in increased production and elevated expression of the IGF-1R ligand IGF-II, 
increased activity of IGF-1R and increased levels of Akt activity. In addition, the A549 
lung cancer cell line, which displays a partial sensitivity to gefitinib, was chronically 
challenged with the inhibitor; the resistant variant that emerged presented with a marked 
adaptive increase in the activity of elements of the IGF-1R pathway. The importance of 
IGF-1R signaling in these various cell types with acquired gefitinib resistance was further 
supported by the observation that they demonstrated an enhanced dependency on IGF-1R 
signaling; they were subsequently more sensitive to growth inhibition by IGF-1R-selective 
tyrosine kinase inhibitors (Jones et al., 2004). Therefore, the dominance of the EGFR 
pathway in parental cells is replaced by the elevated use of the IGF-1R in gefitinib 
resistant cells. However, such growth factor pathway switching can not only result from 
changes occurring during the development of acquired resistance, but also, critically, can 
occur rapidly and modulate initial sensitivity to EGFR-blockade resulting in de novo or 
intrinsic resistance to anti-EGFR agents such as gefitinib. Indeed, although the EGFR and 
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IGF-1R pathways are classically regarded as separate entities, promoting growth utilizing 
overlapping downstream signal transduction molecules indicates that these receptors can 
affect each other’s signaling abilities, although the precise mechanisms involved in this 
crosstalk have not been fully elucidated. For example, gefitinib only partially blocks EGFR 
activity in A549 lung cancer cells and this is accompanied by a dramatic increase in the 
activity but not the expression of IGF-1R. Moreover, in these cells IGF-1R can 
transphosphorylate EGFR, maintaining EGFR activity in the presence of gefitinib. 
Therefore, gefitinib limits its own efficacy by facilitating IGF-1R activity in these cells. 
Interestingly, it was observed that in de novo gefitinib-resistant LoVo colorectal cancer 
cells, which are defective in terms of ability to produce mature IGF-1R and predominantly 
express insulin receptor-isoform A (InsR-A), a close family member of the IGF-1R, insulin 
receptor activity is increased and downstream activated Akt levels are elevated in the 
presence of gefitinib (Jones et al., 2006). Furthermore, InsR can modulate and maintain 
EGFR phosphorylation in these cells. Such rapid and dynamic interplay between EGFR 
and IGF-1R or InsR could play an important role in limiting the anti-tumor activity of 
gefitinib; partial and de novo resistance to the inhibitor has been demonstrated in A549 
and LoVo cells, respectively. 
In HNSCC, it has been found that the use of the combination of both IGF-1R and EGFR 
antibodies was more effective than either single agent alone at reducing cancer cell 
growth (Barnes et al., 2007). There may be a potential benefit in the use of combined anti-
tyrosine kinase receptor directed therapies to treat HNSCC. Slomiany et al. also 
demonstrated the potential for the co-targeting of both IGF-1R and EGFR signaling in 
HNSCC (Slomiany et al., 2007). Furthermore, Rebucci et al. reported that the combination 
of cetuximab with a PI3K inhibitor could be a good therapeutic option in HNSCC 
(Rebucci et al., 2011). 
7. Cross talk between the NFB and STAT3 signaling pathways 
Of interest, whereas the activation of EGFR leads to the rapid tyrosine phosphorylation of 
STAT3 in tyrosine705 and the consequent activation of STAT3-dependent gene 
expression, it was observed that STAT3 tyrosine phosphorylation and the formation of 
active STAT3 DNA-binding complexes are insensitive to the inhibition of EGFR in a large 
fraction of HNSCC cell lines (Sriuranpong et al., 2003). Indeed, 9 of 10 cell lines form a 
representative panel of HNSCC-derived cells showing increased tyrosine phosphorylation 
and activity of STAT3, but constitutive activity of EGFR was present in only 3 of them 
(Sriuranpong et al., 2003). In search for the mechanism responsible for the EGFR-
independent activation of STAT3 in HNSCC cells, it was observed that the activation of 
the gp130 cytokine receptor subunit promoted the phosphorylation of STAT3 in tyrosine 
705 through the activation of intracellular tyrosine kinases of the JAK family. Suprisingly, 
the activation of gp 130 was found to be primarily initiated by IL-6, which, on its secretion 
and release on the cell surface of HNSCC cells in an autocrine fashion. These findings 
suggest that the persistent activation of STAT3 in HNSCC can result from the deregulated 
activity of EGFR or from the autocrine activation of STAT3 by tumor-released cytokines in 
an EGFR-independent fashion. Furthermore, it was found that overexpression of IL-6 in 
HNSCC cells involves increased transcription from the IL-6 promoter, which is dependent 
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on the presence of an intact NFB response element located 63 to 75 bp upstream of the 
IL-6 transcriptional initiation site. Furthermore, inhibition of NFB led to a remarkable 
downregulation of IL-6 gene and protein expression, concomitant with a decreased 
release of other inflammatory cytokines, such as IL-8, IL-10, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF). 
Surprisingly, the blockade of NFB led also to a drastic inhibition of the constitutive 
STAT3 activity in HNSCC cells, as reflected by the reduced tyrosine phosphorylation of 
STAT3. Interestingly, interfering with NFB function also prevented the 
autocrine/paracrine activation of STAT3 in HNSCC cells (Squarize et al., 2006). These 
findings support a cross-talk between the NFB and the STAT3 signaling systems. This 
cross-talk is initiated by the release of IL-6 as a consequence of the NFB-dependent 
activation of the IL-6 promoter, and the subsequent tyrosine phosphorylation of STAT3 by 
the autocrine/paracrine activation of IL-6 receptors in tumor cells. 
8. Future prospects 
Signaling of multiple receptor tyrosine kinases (RTKs) is propagated through Akt. 
Therefore, simultaneous inhibition of EGFR with pathway components such as Akt or 
mTOR could circumvent the feedback activation observed with either approach alone. 
The most extensive data concerning proximal and distal signaling inhibition relates to 
combining PI3kinase/Akt/mTOR pathway inhibitors with EGFR antagonists. Several 
PI3kinase inhibitors can restore sensitivity to EGFR inhibitors. For example, the selective 
pI3kinase inhibitor PX-866 and p110ｚcan abolish gefitinib resistance in NSCLC 
xenografts (Ihle et al., 2005). Synergistic effects of rapamycin and EGFR TKIs have been 
observed in several in vitro systems including glioblastoma multiforme, prostate cancer, 
pancreatic cancer, squamous cell carcinoma, renal cell carcinoma, leukemia, cervical 
carcinoma and NSCLC (Birle  Hedley, 2006; Buck et al., 2006; Costa et al., 2007; 
Hjelmeland et al., 2007; Jimeno et al., 2007; Mohi et al., 2004). Several studies extended 
efficacy of these combinations in the xenograft experiments. Buck et al. (Buck et al., 2006) 
showed re-sensitization and synergistic growth inhibition with the combination of 
rapamycin and erlotinib in cell lines that were previously resistant to erlotinib. Li et al. 
noted significant regression of lung tumors in transgenic mice possessing the secondary 
resistance mutation T790M when treated with a combination of rapamycin and the 
irreversible EGFR TKI, HKI-272 (Li et al., 2007). In human glioma cell lines with mutant 
PTEN, addition of the dual PI3kinase/mTOR inhibitor PI-103 to erlotinib was necessary to 
induce growth arrest (Fan et al., 2007), suggesting that activation of the 
PI3kinase/Akt/mTOR pathway by EGFR-independent mechanisms confers resistance to 
EGFR inhibitors, which can nonetheless be overcome by the addition of pathway 
inhibitors. Collectively, these data suggest that the use of EGFR antagonists with 
PI3kianse/Akt pathway inhibitors could be beneficial to patients that have developed 
resistance to EGFR TKIs.  
However, we think that the use of EGFR antagonists with PI3kinase/Akt pathway inhibitors 
might allow the activation of TNFR and/or IL-1R-NFB-IL6-STAT3 signaling (Fig1). 
Therefore, we recommend the use of EGFR antagonists with PI3kinase/Akt pathway 
inhibitors and NFB-IL6-STAT3 pathway inhibitors. 
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Fig. 1. Cell signalings and the communications in head and neck cancer. 
9. Conclusions 
EGFR is expressed at a high level in HNSCC but EGFR inhibitor monotherapy has limited 
success. Previous studies have demonstrated that EGFR mutations are extremely rare 
inHNSCC; inhibition of PI synthesis provides anti-proliferative, anti-invasive and anti-
angiogenesis effects on HNSCC. The PI3kinase/Akt pathway is responsible for cellular 
survival and there is molecular cross-talk between EGFR and IGF1R signaling through 
PI3kinase/Akt in HNSCC. Furthermore, there is molecular cross-talk between the NFB 
and STAT3 signaling pathways. Therefore, combination therapy targeting PI3kinase/Akt, 
NFB/STAT3, and EGFR signaling pathways should provide clinical benefit for patients 
suffering with HNSCC (Fig. 1). Although various Akt and/or NFB specific inhibitors 
have been developed, we recommend using a combination of an EGFR antagonist with 
numerous chemo-preventive compounds that inhibit the activation of both Akt and NFB 
, as natural compounds have little side effect. Resveratrol, trans-3,5,4,-trihydroxystibene, 
was first isolated in 1940 as a constituent of the root of white hellebore (Veratrum 
grandiflorum O. Loes), but has since been found in various plants including grapes, 
berries and peanuts. In addition to cardioprotective effects, resveratrol exhibits anticancer 
properties as suggested by its ability to suppress proliferation of a wide variety of tumor 
cells. The growth-inhibitory effects of resveratrol are mediated through cell-cycle arrest: 
up-regulation of p21, p53 and Bax, and down-regulation of survivin, cyclin D1, cyclin E, 
Bcl-2, Bcl-xl and cIAPs, and activation of caspases. Resveratrol suppresses the activation 
of several protein kinases including Akt (Banerjee et al., 2010), and limited data from 
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humans suggest that it is pharmacologically safe. Furthermore, resveratrol suppresses 
TNF-induced activation of NFB (Manna et al., 2000). Another chemopreventive agent 
whose effects on Akt signaling have been studied in some detail is the rotenoid deguelin. 
Deguelin is a rotenoid from the African plant Mundulea sericea (Leguminosae), which 
was identified as a potent chemopreventive agent on the basis of its action against 
chemically induced preneoplastic lesions in a mammary organ culture, and its inhibition 
of papillomas in a two-stage mouse skin carcinogenesis model (Nair et al., 2006). 
Furthermore, deguelin suppresses the formation of carcinogen-induced aberrant crypt 
foci in mouse colon (Murillo et al., 2003). More recently, this rotenoid was shown to 
suppress cigarette smoke-induced lung carcinogenesis (Lee et al., 2005), and it enhances 
the sensitivity of leukemia cells to chemotherapeutic agents (Bortul et al., 2005). How 
deguelin mediates its chemopreventive and chemosensitizing effects is not yet fully 
understood, but various mechanisms have been proposed including suppression of the 
PI3kinase/Akt pathway (Chen et al., 2009). In Akt-inducible transgenic mice, deguelin 
was competent at suppressing Akt activation in the lung. At doses achievable in vivo, it 
reduced pAkt levels, induced apoptosis and suppressed proliferation of premalignant and 
malignant human bronchial epithelial cells; minimal effects were observed in normal 
bronchial cells (Chun et al., 2003). Blockade of Akt activation is likely to contribute to the 
pro-apoptotic actions of deguelin in breast cancer cell lines and anti-angiogenic effects in 
vitro. Deguelin inhibited formation of murine lung tumors in conjunction with 
suppression of Akt activation in vivo (Hecht, 2005). Furthermore, deguelin suppresses 
NFB activation induced by various carconogens and inflammatory stimuli including 
TNF and IL-1ǃ (Nair et al., 2006). The cruciferous vegetable component indole-3-carbinol 
has chemopreventive activity that could be associated with down-regulation of Akt 
signaling (Chinni  Sarkar, 2002). Furthermore, indole-3-carbinol suppresses NFB 
activation induced by various carconogens and inflammatory stimuli including TNF and 
IL-1ǃ (Takada et al., 2005). Honokiol, used as a muscle relaxant, is derived from the stem 
and bark of the plant Magnolia officinalis, which is used in traditional Chinese and 
Japanese medicine. Extensive research has demonstrated that honokiol inhibits skin tumor 
promotion, nitric oxide synthesis, TNF expression and inhibits invasion. Furthermore, it 
down-regulates the anti-apoptotic protein bcl-xl, inhibits angiogenesis and tumor growth 
in vivo, induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells 
through down-regulation of the anti-apoptotic protein Mcl-1, and overcomes drug 
resistance in multiple myeloma. Honokiol blocks TNF-induced NFB activation (Ahn et 
al., 2006). Indeed, Honokiol inhibits EGFR signaling involving Akt and STAT3, and 
enhances the antitumor effects of EGFR inhibitors (Leeman-Neill et al., 2010). In 
conclusion, the combination of an EGFR antagonist with these chemo-preventive 
compounds that inhibit the activation of both Akt and NFB may overcome the resistance 
to EGFR antagonist in HNSCC. 
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